ArticleFrontiers in oncology2025
Predictive value of dual-energy CT assessment of extracellular volume fraction on efficacy of immune checkpoint inhibitors in patients with liver cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive value of dual-energy CT assessment of extracellular volume fraction (ECV) on the efficacy of immune checkpoint inhibitors (ICIs) in patients with liver cancer. Methods: A retrospective analysis was conducted on 179 liver cancer patients who received ICIs in our hospital between November 2023 and February 2025. Patients were divided into a group with excellent treatment efficacy (n=103) and a group with poor treatment efficacy (n=76). Univariate and binary Logistics regression analyses were performed to identify factors influencing treatment efficacy. The predictive value of ECV for the efficacy of ICIs in liver cancer patients was evaluated with receiver operating characteristic (ROC) curve analysis. Results: There were statistically significant differences in ECV, CRP, IL-6, NEU, and the status of other anti-tumor treatments between the two groups ( Conclusion: Dual-energy CT assessment of ECV demonstrates good predictive value in the efficacy of ICIs in liver cancer patients, assisting clinical judgment of treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.